New eye drop combo aims to soothe dry eye sufferers

NCT ID NCT07412860

Recruiting now Symptom relief Sponsor: FB Vision S.p.A Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new eye drop (FBV_01) that combines an extra ingredient with hyaluronic acid for people with moderate-to-severe dry eye. About 74 adults will use the drop four times a day for 30 days. Researchers will compare it to hyaluronic acid alone to see if the combo is better at relieving symptoms and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eye drop containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV_01)
What this could lead to: If it works, this could offer a more effective eye drop for people with moderate-to-severe dry eye, improving comfort and reducing symptoms.
What could go wrong: This is a small, early-stage trial with only 74 participants. The improvement over existing drops may be small, and the open-label design could bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE (DED) DRY EYE SYNDROMES

Contacts and locations

Locations

S.C. di Oculistica Azienda Ospedaliero-Universitaria di Cagliari Presidio San Giovanni di Dio
RECRUITING

Cagliari, CA, 09124, Italy
U.O. Oculistica Azienda Ospedaliero-Universitaria Renato Dulbecco
RECRUITING

Catanzaro, CZ, 88100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.